1,472 reports of this reaction
2.5% of all BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE reports
#7 most reported adverse reaction
EMOTIONAL DISTRESS is the #7 most commonly reported adverse reaction for BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE, manufactured by INDIVIOR INC.. There are 1,472 FDA adverse event reports linking BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE to EMOTIONAL DISTRESS. This represents approximately 2.5% of all 59,605 adverse event reports for this drug.
Patients taking BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE who experience emotional distress should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
EMOTIONAL DISTRESS is a less commonly reported adverse event for BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to emotional distress, the following adverse reactions have been reported for BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE:
The following drugs have also been linked to emotional distress in FDA adverse event reports:
EMOTIONAL DISTRESS has been reported as an adverse event in 1,472 FDA reports for BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
EMOTIONAL DISTRESS accounts for approximately 2.5% of all adverse event reports for BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE, making it a notable side effect.
If you experience emotional distress while taking BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.